A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application.

Main Inclusions/Exclusions:
-No metastatic urolithial carcinoma
-No additional malignancies requiring active tx (with some exceptions)
-No contraindications for general or spinal anesthesia
-No active autoimmune disease, or any condition requiring immunosuppressants/steroids
-No history of coagulation issues

Learn more here.